

VPA10815/029/003

Dermipred 20 mg tablets for dogs

Variation	Summary	Date
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	29/10/24
Vet - F.II.f.1 z)	VRA-R - Vet - F.II.f.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.f.1 z) Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	25/09/24
Vet - A2	VNRA - Vet - A2 - Change in the (invented) name of the veterinary medicinal product - A2 Administrative changes: Change in the (invented) name of the veterinary medicinal product	22/04/24
Vet - F.III.1 a) z.	VRA-R - Vet - F.III.1 a) z. - a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 a) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	05/12/22
Vet - F.I.d.1 c)	VRA-R - Vet - F.I.d.1 c) - c) Extension or introduction of a re-test period/storage period supported by real time data - F.I.d.1 c) Quality Changes - Active Substance - Stability -Change in the re-test period/storage period of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - Extension or	05/12/22

	introduction of a re-test period/storage period supported by real time data	
--	---	--